Immunohistochemistry (IHC) for Microsatellite Instability Fact Sheet Frequently Asked Questions What is Lynch Syndrome? Lynch syndrome is a hereditary.

Slides:



Advertisements
Similar presentations
Colon Cancer The life time risk of developing Colon Cancer in the United States in one in sixteen. This means 144,000 new cases a year accounting for.
Advertisements

Clinical background: Patient RM, YoB 1966 Her family were originally referred because of a history of breast and ovarian cancer. BRCA testing found a missense.
Hereditary GI Cancer Syndromes: Keys to identify high risk patients
Universal Screening of Lynch Syndrome Heather Hampel, MS, CGC Clinical Associate Professor, Division of Human Genetics.
Integrating HBOC Screening into Public Health Practice
Gene 210 Cancer Genomics April 29, Key events in investigating the cancer genome M R Stratton Science 2011;331:
Lynch Syndrome and Colorectal Cancer Steven G. Proshan, M.D. Annapolis Colon and Rectal Surgeons Anne Arundel Medical Center November 8,
10 November 2011 Genetic counseling for breast cancer risk Aichu Huang, MS. CGC. Department of Medical Genetics National Taiwan University Hospital.
A few thoughts on cancer and cancer family syndromes Pamela McGrann, MD. Department of Medical Genetics.
COLORECTAL BLEEDING: a multidisciplinary approach Torino, 31 marzo-1 aprile 2006 GENETIC EVALUATION Schena M, Angelini F, Bertetto O. Department of Medical.
Hereditary Factors in Breast Cancer
Understanding Hereditary Cancers Brittany Burnett, MS, CGC Certified Genetic Counselor John Muir/Mt. Diablo Health System Cancer Centers.
Lecture 22 Cancer Genetics II: Inherited Susceptibility to Cancer Stephen B. Gruber, MD, PhD November 19, 2002.
Genetics and Ovarian Cancer Jeanne M. Schilder, M.D. Associate Professor, Gynecologic Oncology Indiana University Medical Center September 19, 2012.
Hereditary Colorectal Cancer: An Overview Felice Schnoll-Sussman,MD Jay Monahan Center for Gastrointestinal Health New York Hospital/ Weill Cornell Medical.
Hereditary Breast & Ovarian Cancer Syndrome HBOC Tammy McKamie RN MSN OCN Cancer Genetics Educator Clinical Oncology Patient Navigator.
Breast Cancer Risk and Risk Assessment Models
Familial Colorectal Cancers Francis M. Giardiello, M.D. The Johns Hopkins University.
Comprehensive IHC Screening for Lynch Syndrome: What You Need to Know Andrea Lewis, MS, CGC January 14, 2010.
Hereditary tumours to be aware of Gerd JACOMEN Dept. of Pathology.
Is Your Patient At Risk of Having Lynch Syndrome? David Strassler, MD Martin’s Point Health Care Biddeford, Maine
Kalyani Maganti, M.D. ASCO Chromosomes, DNA, and Genes Cell Nucleus Chromosomes Gene Protein.
Morning Report May 20, 2009 Bridger Clarke  Born in Lawrence, Massachusetts, on 4 January  Dropped out of high school at the age of fourteen.
SURVIVORS TEACHING STUDENTS: SAVING WOMEN’S LIVES®
Type Of Cancer:Location: CarcinomaEpithelial Cells SarcomaConnective Tissue LeukemiaCirculatory / Lymphatic.
Gene 210 Cancer Genomics May 5, Key events in investigating the cancer genome M R Stratton Science 2011;331:
Functional consequences of NLS mutations in human MLH1 Alex Dukes Dr. Andrew Buermeyer Department of Environmental & Molecular Toxicology Oregon State.
Determining Phenotypes of Pathogenic Mismatch Repair Mutants Brett Palama Lab of Andrew Buermeyer, Ph.D. Dept. of Environmental/Molecular Toxicology.
West Midlands Regional Genetics Laboratory
Genetics & Colorectal Cancer
Cancer Genetics Genetic Disorder. What are cancer genetics? Many cancer-predisposing traits are inherited in an autosomal dominant fashion, that is, the.
The Cancer Pedigree BRCA What?. Outline Introduction: Understanding the weight of genetics in Ovarian Breast Cancer BRCA 1 and BRCA 2 Genes – Function.
Genetics and Ovarian Cancer June 16, 2015 Ovarian Cancer Alliance of Oregon and SW Washington Becky Clark, MS, CGC Genetic Counselor.
GENETIC TESTING: WHAT DOES IT REALLY TELL YOU? Lori L. Ballinger, MS, CGC Licensed Genetic Counselor University of New Mexico Cancer Center.
Angelina Jolie The White Coat Wonder. Rational  The purpose of our research is to enrich the Premed-A community with the knowledge of other cancers caused.
Implementing universal Lynch Syndrome screening in a large healthcare system.
Adult-Onset Disease The Example of Colon Cancer Summer, 2012.
MLH1 & its role in Lynch Syndrome and sporadic colorectal cancers By Annie Jin.
Tumour Analysis-Lynch Syndrome Dr Alan Donaldson Consultant in Clinical Genetics Bristol.
Genetics: For this Generation and the Next
Uterine Cancer Endometrial (or uterine) cancer will account for 50,000 new cases and 8200 deaths in the United States in Two genetic disorders are.
MSH2 and Hereditary Nonpolyposis Colorectal Cancer By Bobby Glenn Warren III.
Understanding Cancer and Related Topics
Talking to Your Family About Your Diagnosis of Hereditary Breast and Ovarian Cancer Syndrome Several of my aunts died of breast cancer, so I was very worried.
Knowledge we should know about CANCER Group members: 吳俊諺 、 謝淯存 、 郭玠廷 、 王珮瑜.
MLH1: Hereditary non- polyposis colon cancer (HNPCC) By: Alison Edge.
Talking to Your Family About Your Diagnosis of Lynch Syndrome When you share information with people, sometimes they feel helpless and don’t want to address.
Translational and Personalized Medicine Initiative: Quality of Care Project Report.
Date of download: 5/31/2016 From: The Hereditary Nonpolyposis Colorectal Cancer Syndrome: Genetics and Clinical Implications[dhelix] Ann Intern Med. 2003;138(7):
Lynch Syndrome or Hereditary Non-Polyposis Colorectal Cancer (HNPCC)
Hereditary Cancer Predisposition: Updates in Genetic Testing
West Midlands Regional Genetics Laboratory
A Retrospective Analysis of Microsatellite Instability testing on colorectal cancer specimens in Queensland Public Hospitals Matthew Burge; Hayden Christie;
Fostering a Collaborative Approach in the Management of BRCA-Mutated Ovarian Cancer.
Hereditary Gastrointestinal Cancers
Li-Fraumeni Syndrome Wendy Kohlmann, MS, CGC
Targeted Next-Generation Sequencing for Hereditary Cancer Syndromes
Genetics and Breast Cancer Adelphi 2018 Educational Forum Sharona Cohen, MS, CGC Certified Genetic Counselor Northwell Health.
The Role of MSH2 in Hereditary Non-Polyposis Colon Cancer
When Should We Suspect Hereditary Colorectal Cancer Syndrome?
Genetic Counseling & Testing for Cancer Risk
Lynch syndrome (LS) Hereditary Non-polyposis Colorectal Cancer (HNPCC)
Representative 3-generation pedigrees for serous cancer probands suggestive of inherited cancer susceptibility. Representative 3-generation pedigrees for.
Noralane M Lindor  Clinical Gastroenterology and Hepatology 
DiagMMR™ assay validation sample collection
Volume 130, Issue 2, Pages (February 2006)
Genetic Testing for Hereditary Colorectal Cancer: Challenges in Identifying, Counseling, and Managing High-Risk Patients  Elena M. Stoffel, Anu Chittenden 
Volume 128, Issue 5, Pages (May 2005)
2019 NAACCR Annual Conference
A, Proportion of variants detected in the MMR genes.
Presentation transcript:

Immunohistochemistry (IHC) for Microsatellite Instability Fact Sheet Frequently Asked Questions What is Lynch Syndrome? Lynch syndrome is a hereditary cancer syndrome associated with a significantly increased lifetime risk for colon, uterine, ovarian, stomach, and other cancers. If identified, patients can receive additional screening and prevention measures to help prevent cancer in the future. How is IHC useful in identifying patients with Lynch syndrome? IHC looks at the four mismatch repair proteins associated with Lynch syndrome. If these proteins are not present in the tumor, this means that the colon cancer could be due to Lynch syndrome. Why was this test done on my patient? Norton Hospital routinely performs IHC for Lynch syndrome on all colorectal resection specimens in order to maximize the identification of patients who are at increased risk for a second cancer and who have family members at significantly increased risk for cancer. Recent studies in the scientific literature have indicated this is the most effective way to identify patients with Lynch syndrome. This process has been approved by the Medical Executive Committee. How is this information helpful to me and my patient? Individuals with Lynch syndrome are at a significantly increased risk for developing cancer in the future. This information will be helpful in determining the ongoing management of your patient and may also aid in treatment decisions or eligibility for research studies. Patients can benefit from this information by understanding the cause of their cancer, their risk for subsequent cancers, and the risks for their family members. The family members of a patient can also be tested for Lynch syndrome, giving them the ability to make screening and prevention decisions that can prevent cancer in the future or allow it to be diagnosed at the earliest possible stage, when the cancer is most treatable. What happens next? If the IHC is normal, this makes it unlikely that the patient has Lynch syndrome. If you still feel the patient needs a referral to the Genetic Counseling Service, please contact the service at If the IHC result is abnormal, the Genetic Counseling Service has been notified and will contact you directly to develop a plan for informing the patient of this result. You may also contact the Genetic Counseling Service directly. The back of this sheet contains interpretations for the various IHC test results.

MLH1Positive (Protein Expressed) MSH2Positive (Protein Expressed) MSH6Positive (Protein Expressed) PMS2Positive (Protein Expressed) This test result indicates that ALL four genes are functioning normally. This patient is very unlikely to have Lynch Syndrome MLH1Positive (Protein Expressed)MSH2 Negative () Negative (Protein Not Expressed) MSH6 PMS2Positive (Protein Expressed) This test result indicates that MSH2 or MSH6 are NOT functioning due to LOH. Patients with this test result have essentially an 100% chance to test positive for a deleterious mutation in the MSH2 gene. MLH1 Negative Negative (Protein Not Expressed) MSH2Positive (Protein Expressed) MSH6Positive (Protein Expressed) PMS2 Negative () Negative (Protein Not Expressed) This test result indicates that MLH1 or PMS2 are NOT functioning due to loss of heterozygosity (LOH). Patient has a 20% chance to have a deleterious MLH1 mutation and a 80% chance to have loss of expression due to hypermethylation of the MLH1 gene. MLH1Positive (Protein Expressed) MSH2Positive (Protein Expressed) MSH6 Negative () Negative (Protein Not Expressed) PMS2Positive (Protein Expressed) This test result indicates that MSH6 is NOT functioning due to LOH. This patient will essentially have a 100% chance to test positive for a deleterious MSH6 mutation. MLH1Positive (Protein Expressed) MSH2Positive (Protein Expressed) MSH6Positive (Protein Expressed) PMS2 Negative (Protein Not Expressed) This test result indicates that PMS2 is NOT functioning due to LOH. This patient will essentially have a 100% chance to test positive for a deleterious PMS2 mutation. IHC for Lynch Syndrome Result Interpretation Charts Please contact the Norton Cancer Institute’s Genetic Counseling Services with additional questions or concerns: Andrea Lewis, MS, CGC Maegan Roberts, MS Phone: